Thank you, Mr. Chair.
I have a question about the announcement of $1.5 billion for rare diseases. One of the officials can surely answer me.
Last time, I brought up people suffering from illnesses like amyotrophic lateral sclerosis, or ALS, who are expected to live three to five years. These individuals can take drugs to extend their lives, but the approval process, up to and including possible reimbursement, takes far too long.
Do you have robust mechanisms in place to fast-track patients suffering from rare diseases specifically?